BONE CANCER THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 24, 1998
filing date -
Jan 26, 1998
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Homing bone marrow cells deposited at ATTC CRL-12424 can be transfected with a toxic gene which expresses a compound which alone, or in the company of a triggering agent, kills neighboring cancer cells in the bone marrow of a patient receiving the therapy. Toxic genes include cytotoxin such as thymidine kinase, immune stimulating compounds such as interleuken-2 and radiation repair inhibitors, such as Ku protein. The transfected cells can be administered directly to the site of the tumor or systemically, or regionally, intramedullary (into the marrow) through intravascular administration. The latter alternative permits the delivery of very high doses of the effective agent.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully